Expert Insights

Bhagirathbhai R. Dholaria, MBBS, highlights findings from the TRiMM-2 trial, which demonstrated that the combination of talquetamab and daratumumab was safe and effective for patients with R/R multiple myeloma.

Dorota Goplen, MD, Haukeland University Hospital, Bergen, Norway, discusses results from a phase 1b/2 BORTEM-17 study evaluating the efficacy of sequential treatment with bortezomib and temozolomide for patients with glioblastoma and...

At the 2023 ASCO Annual Meeting, Jason Luke, MD, shares results from the protocol-specified final distant metastasis-free survival analysis of KEYNOTE-716, evaluating adjuvant pembrolizumab among patients with stage IIIB and IIIC resected...

At the 2023 ASCO Annual Meeting, Helen Moon, MD, discusses results from a study investigating the real world response rates of patients with urothelial carcinoma treated with first-line platinum-based chemotherapy, to assess the uptake of...

Yutaka Yamamoto, MD, discusses OS results from the phase 3 PRECIOUS trial evaluating pertuzumab retreatment in patients with HER2-positive locally advanced or metastatic breast cancer.

Sara Tolaney shares the final overall survival analysis of the phase 3 TROPiCS-02 trial, evaluating sacituzumab govitecan in pretreated metastatic HR-positive breast cancer, which was presented at the 2023 ASCO Annual Meeting

At the 2023 American Society of Clinical Oncology Annual Meeting, Nirav Niranjan Shah, MD, shared findings from a phase 2 trial of split-dose R-CHOP for older patients with DLBCL.

At the 2023 ASCO Annual Meeting, Binod Dhakal, MD, presented phase 3 results from CARTITUDE-4 on the use of ciltacabtagene autoleucel therapy versus the standard of care therapy for patients with lenalidomide-refractory multiple myeloma.

Matthew Ballo, MD, discusses results from a meta-analysis of comparative studies showing a significant survival benefit with tumor treating fields therapy added to standard radiochemotherapy for patients with newly diagnosed glioblastoma.